Cagrilintide vs Hexarelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Hexarelin
Hexarelin is a potent synthetic hexapeptide growth hormone secretagogue. It provides the strongest GH release among GHRPs but is associated with rapid desensitization of receptors.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Hexarelin |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Acts as a ghrelin mimetic with high potency at the GHS receptor. Provides powerful GH release but receptor desensitization occurs faster than with other GHRPs, requiring cycling. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Typical dosing: 100-200mcg administered 2-3 times daily for 4-6 weeks, followed by an equal off period to allow receptor resensitization. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Subcutaneous injection. Cycling is essential to maintain effectiveness. Often used in short bursts rather than continuous protocols. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Water retention, cortisol and prolactin increase, hunger (moderate), tingling, and potential blood pressure effects. |
| Best For |